prof. Sylvie Rottey (MD, PhD)

CRIG group leader
Sylvie Rottey

Head of clinic in the Department of Medical Oncology
Head of the Drug Research Unit Ghent - especially performing phase I trials first in humans - healthy volunteers and oncology 
Medical Oncologist
Clinical Pharmacologist
Professor in Pharmacology


Research focus

Phase I trials in Oncology, first in humans and other

Research team

Key publications

  • CD70 Expression and Its Correlation with Clinicopathological Variables in Squamous Cell Carcinoma of the Head and Neck, Pathobiology. 2016;83(6):327-33. doi: 10.1159/000446569. Epub 2016 Jul 8. PubMed (PMID: 27389010)
  • Abiraterone acetate post-docetaxel for metastatic castration-resistant prostate cancer in the Belgian compassionate use program. Urol Oncol. 2016 Jun;34(6):254.e7-254.e13. doi: 10.1016/j.urolonc.2015.12.017. Epub 2016 Feb 2. (PubMed PMID: 26850781)
  • Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma. BJU Int. 2016 Sep;118(3):408-15. doi:10.1111/bju.13415. Epub 2016 Feb 11. (PubMed PMID: 26779597)
  • Biomarker Analysis in a Phase II Study of Sunitinib in Patients with Advanced Melanoma. Anticancer Res. 2015 Dec;35(12):6893-9. (PubMed PMID: 26637913)
  • Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015 Nov 5;373(19):1803-13. doi: 10.1056/NEJMoa1510665. Epub 2015 Sep 25. (PubMed PMID: 26406148)
  • A phase I study of volasertib combined with afatinib, in advanced solid tumors. Cancer Chemother Pharmacol. 2015 Oct;76(4):843-51. doi: 10.1007/s00280-015-2860-2. Epub 2015 Sep 8. (PubMed PMID: 26349473)
  • CD70: An emerging target in cancer immunotherapy, Pharmacol Ther. 2015 Nov;155:1-10. doi: 10.1016/j.pharmthera.2015.07.007. Epub 2015 Jul 26. Review. (PubMed PMID: 26213107)
  • Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. Lancet Oncol. 2015 May;16(5):583-94. doi: 10.1016/S1470-2045(15)70124-5. Epub 2015 Apr 16. (PubMed PMID: 25892145)